After receiving accreditation from the Japanese Ministry of Health for its Patalganga facility, Elder Pharmaceuticals is planning to enter into the Japanese pharma market during the current fiscal.
The Japanese pharmaceutical market is valued at about $70 billion. The company’s planning to acquire about 1-2% of the market share.
The company is positioning itself to become a supplier of active pharmaceutical ingredients (APIs) and advanced intermediates to tap the vital Japanese market for the future growth of the company. The company’s plant at Patalganga manufactures APIs.
Elder Pharmaceuticals has also developed two products going off-patent in the Japanese market in 2014. One of the products is from the central nervous system (CNS) category and the second is from the gastrointestinal (GI) segment.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: